- $747.45m
- $738.73m
- $143.27m
- 57
- 30
- 76
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.21 | ||
| Price to Tang. Book | 8.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.73% | ||
| Return on Equity | -18.93% | ||
| Operating Margin | -45.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 27.37 | 48.09 | 119.16 | 161.76 | 143.27 | 113.66 | 137.83 | 48.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to improve quality and de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. Its products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Its bioproduction tools and services are comprised of three lines: Cell processing, Freezers and thaw systems and Biostorage services. Its proprietary biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death. Its ThawSTAR line includes thawing products that control the temperature and timing of the thawing process of biologic material. It operates five storage facilities in the United States and one facility in the Netherlands.
Directors
- Michael Rice CHM (58)
- Roderick de Greef PRE (60)
- Troy Wichterman CFO
- Aby Mathew EVP (49)
- Todd Berard CMO (52)
- Sarah Aebersold VPR (46)
- Karen Foster OTH (61)
- Marcus Schulz OTH (43)
- Amy DuRoss IND (47)
- Rachel Ellingson IND (51)
- Joydeep Goswami IND (49)
- Joseph Schick IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 25th, 1998
- Public Since
- November 22nd, 1989
- No. of Shareholders
- 256
- No. of Employees
- 409
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 45,300,000
- Address
- SUITE 310, 3303 MONTE VILLA PARKWAY, BOTHELL, 98021
- Web
- https://www.biolifesolutions.com/
- Phone
- +1 4254011400
- Contact
- Troy Wichterman
- Auditors
- BDO USA, LLP
Upcoming Events for BLFS
Biolife Solutions Inc Annual Shareholders Meeting
Q2 2024 BioLife Solutions Inc Earnings Release
Similar to BLFS
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the BioLife Solutions share price?
As of Today at 19:04 UTC, shares in BioLife Solutions are trading at $16.50. This share price information is delayed by 15 minutes.
How has the BioLife Solutions share price performed this year?
Shares in BioLife Solutions last closed at $16.50 and the price had moved by -22.79% over the past 365 days. In terms of relative price strength the BioLife Solutions share price has underperformed the S&P500 Index by -37.64% over the past year.
What are the analyst and broker recommendations for BioLife Solutions?
The overall consensus recommendation for BioLife Solutions is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BioLife Solutions dividend yield?
BioLife Solutions does not currently pay a dividend.
Does BioLife Solutions pay a dividend?
BioLife Solutions does not currently pay a dividend.
When does BioLife Solutions next pay dividends?
BioLife Solutions does not currently pay a dividend.
How do I buy BioLife Solutions shares?
To buy shares in BioLife Solutions you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioLife Solutions?
As of the previous close price of $16.50, shares in BioLife Solutions had a market capitalisation of $747.45m.
Where are BioLife Solutions shares listed?
Here are the trading details for BioLife Solutions:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BLFS
What kind of share is BioLife Solutions?
Based on an overall assessment of its quality, value and momentum BioLife Solutions is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioLife Solutions share price forecast for 2024?
The analyst consensus target price for shares in BioLife Solutions is $23.13. That is 40.18% above the last closing price of $16.50.
Analysts covering BioLife Solutions currently have a consensus Earnings Per Share (EPS) forecast of -$1.02 for the next financial year.
What is the trend in the BioLife Solutions share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioLife Solutions. Over the past six months, its share price has outperformed the S&P500 Index by +16.89%.
As of the last closing price of $16.50, shares in BioLife Solutions were trading +6.31% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioLife Solutions PE Ratio?
The BioLife Solutions PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioLife Solutions?
BioLife Solutions' management team is headed by:
- Michael Rice - CHM
- Roderick de Greef - PRE
- Troy Wichterman - CFO
- Aby Mathew - EVP
- Todd Berard - CMO
- Sarah Aebersold - VPR
- Karen Foster - OTH
- Marcus Schulz - OTH
- Amy DuRoss - IND
- Rachel Ellingson - IND
- Joydeep Goswami - IND
- Joseph Schick - IND